There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SAGE Therapeutics (SAGE) and Rocket Pharmaceuticals (RCKT) with bullish sentiments.
SAGE Therapeutics (SAGE)
Morgan Stanley analyst Matthew Harrison reiterated a Buy rating on SAGE Therapeutics today and set a price target of $125.00. The company’s shares closed last Monday at $60.18, close to its 52-week low of $56.50.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 10.4% and a 58.7% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SAGE Therapeutics with a $119.73 average price target, an 111.4% upside from current levels. In a report issued on November 25, RBC Capital also reiterated a Buy rating on the stock with a $235.00 price target.
See today’s analyst top recommended stocks >>
Rocket Pharmaceuticals (RCKT)
In a report released today, Madhu Kumar from Robert W. Baird reiterated a Buy rating on Rocket Pharmaceuticals, with a price target of $41.00. The company’s shares closed last Monday at $19.71, close to its 52-week high of $20.79.
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 16.1% and a 49.7% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Cellular Biomedicine Group, Audentes Therapeutics, and Anchiano Therapeutics.
Currently, the analyst consensus on Rocket Pharmaceuticals is a Strong Buy with an average price target of $30.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
